PDX MINIMUM INFORMATION STANDARD

The PDX Minimal Information document represents the results of a broad community effort to develop a standard regarding the essential information needed to describe a PDX model. This work was published in the dedicated informatics issue of Cancer Research (Nov. 2017) and is serving as the basis for the PDX Finder’s comprehensive search and attribute filtering options (e.g., tumor histology, molecular variant, drug response). The minimal information standard will be an evolving resource based on community feedback.

Comments about the standards are welcome and can be sent to MGI User Support Be sure to include “PDX MI” as the Subject.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Authors

Terrence F. Meehan1*, Nathalie Conte1*, Theodore C. Goldstein2, Giorgio Inghirami3, Mark A. Murakami4, Sebastian Brabetz5,6, Zhiping Gu7, Jeffrey A. Wiser7, Patrick Dunn7, Dale A. Begley8, Debra M. Krupke8, Andrea Bertotti9, Alejandra Bruna10, Matthew Brush11, Annette T. Byrne12, Carlos Caldas10, Amanda L. Christie4, Dominic Clark1, Heidi Dowst13, Jonathan R. Dry14, James Doroshow15, Olivier Duchamp16, Yvonne A. Evrard17, Stephane Ferretti18, Kristopher K. Frese19, Neal C. Goodwin20, Danielle M. Greenawalt21, Melissa A. Haendel11, Els Hermans22, Peter J. Houghton23, Jos Jonkers24, Kristel Kemper24, Tin O. Khor25, Michael T. Lewis26, KC Kent Lloyd27, Jeremy C. Mason1, Enzo Medico9, Steven B. Neuhauser8, Jim M. Olson28, Daniel S. Peeper24, Oscar M. Rueda10, Je Kyung Seong29, Livio Trusolino9, Emilie Vinolo30, Robert J. Wechsler-Reya31, David M. Weinstock4, Alana Welm32, Saravut J. Weroha33, Frédéric Amant24,34, Stefan M Pfister 5,6,35, Marcel Kool5, Helen Parkinson1, Atul J. Butte2, Carol J. Bult8

* = These authors contributed equally to the manuscript

Institutes

1European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, UK. 2Institute for Computational Health Sciences, University of California, San Francisco, USA. 3Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, USA. 4Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA. 5Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 6German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. 7Northrop Grumman Information Systems Health IT, Rockville, USA. 8The Jackson Laboratory, Bar Harbor, USA. 9Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, Torino, Italy. 10Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, United Kingdom. 11Department of Medical Informatics and Clinical Epidemiology and OHSU Library, Oregon Health & Science University, Portland, USA. 12Royal College of Surgeons in Ireland, Ireland. 13Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, USA. 14Oncology Innovative Medicines and Early Development, AstraZeneca R&D Boston, Waltham, MA, USA. 15Center for Cancer Research, National Cancer Institute, USA. 16Oncodesign Biotechnology, and IMODI consortium, France. 17Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, USA. 18Oncology Disease Area, Novartis Institutes for Biomedical Research, Switzerland. 19Cancer Research UK Manchester Institute, The University of Manchester, United Kingdom. 20Champions Oncology, Baltimore, USA. 21 Translational Bioinformatics
Bristol-Myers Squibb, Pennington, New Jersey USA. 22Katholieke Universiteit Leuven, Leuven, Belgium. 23Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, USA. 24The Netherlands Cancer Institute, Amsterdam, Netherlands. 25MD Anderson Cancer Center, USA. 26The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, USA. 27Department of Surgery, School of Medicine, and Mouse Biology Program, University of California Davis, Davis, USA. 28Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital, USA. 29Research Institute for Veterinary Science and Korea Mouse Phenotyping Center, Seoul , Republic of Korea. 30Seeding Science SAS, Paris, France. 31Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, La Jolla, USA. 32Huntsman Cancer Institute, University of Utah, Salt Lake City, USA. 33Department of Oncology, Mayo Clinic College of Medicine, Rochester, USA. 34University of Leuven, Leuven, Belgium. 35Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany.